{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:08:13Z","timestamp":1777486093889,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cherubism is a rare autosomal dominant skeletal dysplasia, affecting the maxilla and\/or mandible. The condition typically has childhood onset, followed by progression until puberty, with subsequent regression. Cherubism lesions share histological features with giant cell tumor of bone, where high-dose monthly denosumab is an effective medical treatment. Therefore, high-dose denosumab has also been trialed in children with cherubism with positive outcomes. However, the role of denosumab in adult cherubism, particularly a lower dose and frequency, has not been established. We present the case of a 60-year-old man with cherubism, reviewed for a new 39\u2009\u00d7\u200921\u00a0mm left mandibular lesion. The patient had multiple surgeries up to the age of 30 for tumors in the right maxilla and mandible. Given the impact of further surgery on his appearance and quality of life, the patient was referred to Endocrinology for consideration of medical therapy. His bone turnover markers were slightly elevated with normal calcium, phosphate, 25-OH vitamin D, and parathyroid hormone levels. A bone density scan showed lumbar spine osteopenia. He was commenced on 60\u00a0mg denosumab 6-monthly with excellent clinical and radiological responses over the next 30\u00a0months. The most recent CT mandible showed a sustained reduction in the lesion size, measuring 36\u2009\u00d7\u200918\u00a0mm, with osteoid formation and improvement in cortical thinning. Surgery is no longer indicated. No adverse effects from denosumab were reported in the patient. This is the first study to report the efficacy and safety of a low-dose denosumab regimen in the management of cherubism. This treatment approach was able to prevent major surgery and minimize denosumab-related adverse effects. While the optimal treatment duration remains unclear, the patient will continue with 60\u00a0mg denosumab 6-monthly in the short-term given the favorable response. In summary, a low-dose denosumab regimen should be considered for patients with cherubism, particularly those with contraindications or preferences to avoid surgery.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziae164","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:14:12Z","timestamp":1734160452000},"source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of adult cherubism with a 60\u00a0mg denosumab 6-monthly regimen"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7406-165X","authenticated-orcid":false,"given":"Minh V","family":"Le","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital , Melbourne, VIC 3050 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Sim","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Royal Melbourne Hospital , Melbourne, VIC 3050 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapilan","family":"Varatharajah","sequence":"additional","affiliation":[{"name":"Department of Radiology, Royal Melbourne Hospital , Melbourne, VIC 3050 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Royal Melbourne Hospital , Melbourne, VIC 3050 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J","family":"Yates","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital , Melbourne, VIC 3050 ,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne , Melbourne, VIC 3010 ,","place":["Australia"]},{"name":"Department of Endocrinology and Diabetes, Western Health , Melbourne, VIC 3021 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"1","key":"2025011806505943500_ref1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijom.2020.05.021","article-title":"Cherubism: a systematic literature review of clinical and molecular aspects","volume":"50","author":"Chrcanovic","year":"2021","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"2025011806505943500_ref2","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1750-1172-7-S1-S6","article-title":"Cherubism: best clinical practice","volume":"7","author":"Papadaki","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"2025011806505943500_ref3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1750-1172-7-S1-S5","article-title":"The role of SH3BP2 in the pathophysiology of cherubism","volume":"7","author":"Reichenberger","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2025011806505943500_ref4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/88832","article-title":"Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism","volume":"28","author":"Ueki","year":"2001","journal-title":"Nat Genet"},{"issue":"1","key":"2025011806505943500_ref5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cell.2006.10.047","article-title":"Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 \"cherubism\" mice","volume":"128","author":"Ueki","year":"2007","journal-title":"Cell"},{"issue":"3","key":"2025011806505943500_ref6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/or.15.3.589","article-title":"Expression of c-Src and comparison of cytologic features in cherubism, central giant cell granuloma and giant cell tumors","volume":"15","author":"Wang","year":"2006","journal-title":"Oncol Rep"},{"issue":"4","key":"2025011806505943500_ref7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00223-021-00935-z","article-title":"Clinical and radiologic response of central Giant cell granuloma to denosumab: a 6-year prospective observational study","volume":"110","author":"Rhou","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2025011806505943500_ref8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/jbm4.10010","article-title":"Improvement of giant cell lesions of the jaw treated with high and low doses of denosumab: a case series","volume":"1","author":"Kim","year":"2017","journal-title":"JBMR Plus"},{"issue":"4","key":"2025011806505943500_ref9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/CCO.0000000000000529","article-title":"Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone","volume":"31","author":"Lipplaa","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"12","key":"2025011806505943500_ref10","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025011806505943500_ref11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"2025011806505943500_ref12","volume-title":"Giant Cell Tumour of Bone Denosumab 2024 V.3, eviQ Cancer Treatments Online"},{"issue":"2","key":"2025011806505943500_ref13","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.5037\/jomr.2010.1202","article-title":"Cherubism: clinicoradiographic features and treatment","volume":"1","author":"Lima Gde","year":"2010","journal-title":"J Oral Maxillofac Res"},{"issue":"4","key":"2025011806505943500_ref14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.coms.2005.06.004","article-title":"Advances in diagnosis and management of fibro-osseous lesions","volume":"17","author":"Papadaki","year":"2005","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"2025011806505943500_ref15","doi-asserted-by":"publisher","first-page":"1104025","DOI":"10.3389\/fendo.2023.1104025","article-title":"Pharmacological management of cherubism: a systematic review","volume":"14","author":"Cailleaux","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2025011806505943500_ref16","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.joms.2020.06.016","article-title":"Positive outcomes of denosumab treatment in 2 patients with cherubism","volume":"78","author":"Bar Droma","year":"2020","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"2025011806505943500_ref17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1515\/jpem-2019-0581","article-title":"Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism","volume":"33","author":"Kawamura","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"10","key":"2025011806505943500_ref18","doi-asserted-by":"publisher","first-page":"e10210","DOI":"10.1002\/jbm4.10210","article-title":"Use of Denosumab in children with osteoclast bone dysplasias: report of three cases","volume":"3","author":"Upfill-Brown","year":"2019","journal-title":"JBMR Plus"},{"key":"2025011806505943500_ref19","article-title":"Cherubism in 8 years-old child: treatment experience","volume":"1","author":"Kugushev","year":"2018","journal-title":"MOJ Tumor Res"},{"key":"2025011806505943500_ref20","doi-asserted-by":"publisher","first-page":"1533033819840000","DOI":"10.1177\/1533033819840000","article-title":"Malignancy in giant cell tumor of bone: a review of the literature","volume":"18","author":"Palmerini","year":"2019","journal-title":"Technol Cancer Res Treat"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae164\/61157107\/ziae164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/2\/ziae164\/61157107\/ziae164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/2\/ziae164\/61157107\/ziae164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T06:51:12Z","timestamp":1737183072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziae164\/7923455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae164","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,13]]},"article-number":"ziae164"}}